Suven are to begin Phase I trials of 5-HT6 antagonist SUVN-502 intended for the treatment of Alzheimer’s disease.… more →
GPCR Newscrimsoncanary wrote 1 year ago: Suven are to begin Phase I trials of 5-HT6 antagonist SUVN-502 intended for the treatment of Alzheim … more →
crimsoncanary wrote 1 year ago: GSK have published a series of Tricyclic Azepine derivative 5HT6 antagonists … more →
crimsoncanary wrote 1 year ago: Data presented at ICAD-2008 show Suven’s 5-HT6 antagonist SUVN-502 to be effective in preclini … more →
crimsoncanary wrote 1 year ago: Alzheimer’s Association International Conference show Memory Pharmaceutical’s 5-HT6 anta … more →
crimsoncanary wrote 1 year ago: Data prsented at the Schizophrenia International Research Society meeting show Lilly’s long ac … more →
crimsoncanary wrote 1 year ago: Memory Pharmaceuticals has selected MEM-68626 as its lead 5-HT6 Antagonist for the treatment of cogn … more →